Ndyomugyenyi 2011 UGA.

Methods	Trial design: individually RCT Data collected: 2004 to 2008 Length of follow‐up: from first antenatal visit to 28 days after delivery Frequency of follow‐up: regularly through ANC clinics, and every seven days postnatally
Participants	Parity: all parities Number: 5775 randomized; 4715 singleton births followed up Inclusion criteria: pregnant women < 27 weeks at first clinic visit Excluded: > 26 weeks pregnant, non‐residents and temporary residents
Interventions	ITNs + placebo ITNS + IPT IPT Drugs given under direct observation. Two doses of SP.
Outcomes	Prevalence of maternal anaemia (Hb < 11.0 g/L) mean Hb at 36 to 40 weeks Clinical malaria Peripheral and placental parasitaemia Abortions, preterm births, stillbirths, perinatal deaths, neonatal deaths Low birthweight Mean birthweight
Notes	Location: Kabale Highlands, Uganda Urban/rural: rural Malaria transmission: low/unstable area Drug resistance: SP thought to be effective HIV: low Funding: Gates Partnership
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"computer‐generated random number list".
Allocation concealment (selection bias)	Low risk	"individual sealed envelopes".
Blinding (performance bias and detection bias) All outcomes	Low risk	"Tablets of SP or placebo, identical in shape and colour".
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"All study participants, health staff and researchers were blind to drug assignment (SP or placebo)".
Incomplete outcome data (attrition bias) All outcomes	Low risk	Delivery follow‐up: 92%, 92%, and 93% to one month.
Selective reporting (reporting bias)	Low risk	No evidence of selective reporting.
Other bias	Low risk	None identified.